Zylö Receives $600,000 NIH Phase I Grant to Develop a Novel Therapeutic to Treat Onychomycosis (Nail Fungus) Funds to be used to optimize a formulation and prepare for scale-up and IND-enabling studies GREENVILLE, SC, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the Z-pod®...

Onychomycosis Treatment Market Anticipated to Expand with a CAGR of 7% During 2021-2031 Amidst Increased Awareness & Improvement in Healthcare Infrastructure - Future Market Insights, Inc. NEWARK, Del, July 06, 2022 (GLOBE NEWSWIRE) -- As per the recent edition of the Onychomycosis Treatment Market report, ESOMAR-certified market research and consulting firm Future Market Insights...

SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment MORRISVILLE, N.C., May 17, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that data from the Company’s onychomycosis development program with SB208 gel...

Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference MORRISVILLE, N.C., Jan. 11, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that Phase 2 efficacy and safety data for SB208, a topical, silicone-based...

Novan Reports Positive Topline Results with SB208 in Phase 2 Trial MORRISVILLE, N.C., April 12, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced positive topline results from the Company’s Phase 2 clinical trial with...